Processa Pharmaceuticals Stock Price

0.18 (2.09%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Processa Pharmaceuticals Inc PCSA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.18 2.09% 8.80 20:00:00
Open Price Low Price High Price Close Price Prev Close
8.62 8.31 9.03 8.80 8.62
Bid Price Ask Price Spread News
6.00 12.23 6.23 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
421 46,437 $ 8.75 $ 406,438 36,841 3.40 - 14.2399
Last Trade Time Type Quantity Stock Price Currency
16:00:01 857 $ 8.80 USD

Processa Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 92.98M 10.57M 7.64M $ - $ - -0.71 -6.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 74.50k 16.00%

more financials information »

Processa Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PCSA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week10.9810.988.319.3074,705-2.18-19.85%
1 Month13.2513.38928.3110.38110,001-4.45-33.58%
3 Months6.6914.23995.8610.5288,5492.1131.54%
6 Months4.5014.23994.059.3459,8684.3095.56%
1 Year3.8014.23993.408.5964,9795.00131.58%
3 Years3.8014.23993.408.5964,9795.00131.58%
5 Years3.8014.23993.408.5964,9795.00131.58%

Processa Pharmaceuticals Description

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on the development of drug products that are intended to improve the survival and quality of life for patients who have an unmet medical need. The company's lead product, PCS-499 is an oral tablet that is an analog of an active metabolite of an already approved drug. It focuses on fibrotic related diseases such as focal segmental glomerulosclerosis, idiopathic pulmonary fibrosis or Scleroderma.

Your Recent History
Processa P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.